Prelude Therapeutics Incorporated

NasdaqGS:PRLD Stock Report

Market Cap: US$51.8m

Prelude Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PRLD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Mar 25BuyUS$467,438Krishna VaddiIndividual675,000US$0.69
25 Mar 25BuyUS$69,250Andrew CombsIndividual100,000US$0.69
21 Mar 25BuyUS$14,909Krishna VaddiIndividual20,416US$0.73
17 Mar 25BuyUS$29,460Krishna VaddiIndividual39,105US$0.75
13 Mar 25BuyUS$69,564Krishna VaddiIndividual97,500US$0.72
31 Dec 24BuyUS$6,044Krishna VaddiIndividual5,000US$1.21
30 Dec 24BuyUS$12,000Krishna VaddiIndividual10,000US$1.20
23 Dec 24BuyUS$85,538Andrew CombsIndividual63,075US$1.37
19 Dec 24BuyUS$99,326Krishna VaddiIndividual106,888US$0.93
19 Dec 24BuyUS$22,638Bryant LimIndividual25,000US$0.91

Insider Trading Volume

Insider Buying: PRLD insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PRLD?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,441,0607.87%
General Public6,548,18811.6%
Institutions11,587,06220.5%
VC/PE Firms16,589,44229.4%
Hedge Funds17,288,70930.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 86.22% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
30.6%
Baker Bros. Advisors LP
17,288,709US$15.9m-0.03%0.16%
29.4%
OrbiMed Advisors LLC
16,589,442US$15.2m0%0.24%
5.52%
Krishna Vaddi
3,117,278US$2.9m36.4%no data
3.03%
Boxer Capital Management, LLC
1,708,187US$1.6m0%0.16%
1.89%
BlackRock, Inc.
1,069,773US$982.5k1.08%no data
1.82%
T. Rowe Price Group, Inc.
1,029,199US$945.2k-25.4%no data
1.79%
The Vanguard Group, Inc.
1,010,392US$927.9k-1.11%no data
1.18%
Jacobs Levy Equity Management Inc
666,574US$612.2k281%no data
1.12%
Renaissance Technologies LLC
634,500US$582.7k222%no data
0.98%
Blue Sky Trust, Endowment Arm
551,776US$506.7k0%no data
0.89%
Paul Friedman
500,098US$459.3k0%no data
0.88%
Massachusetts Financial Services Company
494,497US$454.1k-10%no data
0.86%
Acadian Asset Management LLC
485,381US$445.8k555%no data
0.85%
Andrew Combs
480,123US$440.9k27.1%no data
0.82%
Millennium Management LLC
462,555US$424.8k188%no data
0.71%
Geode Capital Management, LLC
402,336US$369.5k2.71%no data
0.69%
Marshall Wace LLP
392,155US$360.2k9.19%no data
0.65%
Morgan Stanley, Investment Banking and Brokerage Investments
365,159US$335.4k13.4%no data
0.53%
Two Sigma Advisers, LP
300,000US$275.5k526%no data
0.52%
State Street Global Advisors, Inc.
293,396US$269.5k2.57%no data
0.41%
Two Sigma Investments, LP
231,839US$212.9k307%no data
0.33%
Peggy Scherle
185,685US$170.5k2.77%no data
0.28%
TD Asset Management, Inc.
160,652US$147.5k0%no data
0.23%
Goldman Sachs Group, Investment Banking and Securities Investments
129,664US$119.1k0%no data
0.22%
Deutsche Asset & Wealth Management
123,899US$113.8k748%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/02 04:09
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prelude Therapeutics Incorporated is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Tazeen AhmadBofA Global Research
Reni BenjaminCitizens JMP Securities, LLC